Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Diakonos Oncology’s dendritic cell vaccine shows promise despite development hurdles, says GlobalData

Cellipoint Bioservices entered an agreement with Diakonos Oncology in October 2023 for the development and manufacturing of DOC1021, an autologous dendritic cell (DC) vaccine. The collaboration was announced after Diakonos Oncology revealed promising results of the ongoing Phase I trial evaluating DOC1021 in newly diagnosed patients with glioblastoma multiforme (GBM) administered following surgical intervention and […]
Read more

Supernus’ SPN-830 will face fiercely competitive Parkinson’s market if approved by FDA, says GlobalData

Supernus Pharmaceuticals recently announced that it has resubmitted a New Drug Application (NDA) for its subcutaneous apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations in Parkinson’s Disease (PD). However, as advancement in drug formulations and delivery systems is one of the most rapidly changing areas in PD treatment, SPN-830 is set to […]
Read more

AstraZeneca’s Tagrisso to lead lung cancer small molecule market with over $7 billion sales by 2029, says GlobalData

In the ever-evolving landscape of oncology, small-molecule drugs are carving a significant niche in lung cancer treatment. In 2015, AstraZeneca’s Tagrisso  achieved landmark approval from the FDA following the results of the Phase III AURA trial. This approval marked a significant advancement in the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC). […]
Read more

Alvotech’s AVT05 emerges as leading contender for Simponi biosimilar in rheumatoid arthritis, says GlobalData

The patent for Janssen’s second-generation, tumour necrosis factor-alpha (TNF)-a inhibitor Simponi (golimumab), is scheduled to expire in 2024 and in 2025 in the US and EU, respectively. As patent expiration approaches, strategic activity within this space indicates that the landscape is shifting. In May 2023, Alvotech and Advanz Pharma announced an extended strategic partnership with […]
Read more

Patient comfort in AI-driven healthcare linked to familiarity, finds GlobalData

As the healthcare landscape undergoes transformation due to factors like aging populations, rising chronic diseases, and shifts in lifestyle choices, technology, particularly artificial intelligence (AI), is playing an increasingly vital role. A recent survey highlights how patients’ familiarity with AI significantly influences their comfort level when considering healthcare facilities utilizing this technology, according to GlobalData, […]
Read more

Steatosis-associated fibrosis estimator algorithm offers hope for early detection and management of NAFLD/NASH, says GlobalData

A novel diagnostic tool, the steatosis-associated fibrosis estimator (SAFE) algorithm, may revolutionize the early detection of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). NAFLD, a common liver condition, often remains undiagnosed until advanced stages. The SAFE algorithm offers promising potential to enhance patient identification, enabling proactive healthcare interventions and alleviating the burden on […]
Read more

Novo Nordisk Wegovy’s NHS access marks milestone in obesity treatment, but challenges remain, says GlobalData

Novo Nordisk‘s obesity medication Wegovy (semaglutide) will soon be accessible through the National Health Service (NHS) in England, albeit with limited supply. To maintain controlled distribution, the National Institute for Health and Clinical Excellence (NICE) will implement eligibility criteria, focusing on patients with comorbidities and specific BMI ranges. Although expected to become a leading obesity […]
Read more

Intercept acquisition by Alfasigma reflects NASH failure, says GlobalData

The acquisition of Intercept Pharmaceuticals by the Italian pharmaceutical company Alfasigma became inevitable due to the failed development of Intercept’s flagship asset, obeticholic acid, as a treatment for non-alcoholic steatohepatitis (NASH). With no advanced assets left in its pipeline and rapidly declining share prices, Intercept had a compelling reason to pursue acquisition, says GlobalData, a […]
Read more

GlobalData highlights importance of World Contraception Day in promoting patient education and choice in female contraception

September 26 marks World Contraception Day across the world. An essential gap in the realm of female contraception revolves around educating patients about the diverse contraceptive options at their disposal. World Contraception Day plays a vital role in promoting awareness regarding available contraceptive methods, empowering young individuals to make well-informed decisions regarding their sexual health, […]
Read more

New generics in idiopathic pulmonary fibrosis space will provide more access to patients, says GlobalData

The idiopathic pulmonary fibrosis (IPF) market is underserved with just two licensed pharmaceutical treatments which are available globally, Roche’s Esbriet/Pirespa (pirfenidone) and Boehringer Ingelheim’s (BI) Ofev (nintedanib), which were both approved by the FDA in 2014. Since the patent expiration of Esbriet in 2021, new generic versions have begun entering the IPF space providing more […]
Read more

Forxiga looking for expanded approval to differentiate in HF space fails in DICTATE-AHF trial, says GlobalData

At the 2023 European Society of Cardiology (ESC) Congress, study results found that early initiation of Forxiga (dapagliflozin) failed to improve diuretic efficiency in hospitalized patients with acute decompensated heart failure (ADHF). Specifically, the DICTATE-AHF trial set out to evaluate whether early initiation of Forxiga within the first day of hospitalization could optimize guideline directed […]
Read more

Relmada Therapeutics antidepressant REL-1017 shows promise but requires additional data, opines GlobalData

Following the news that Relmada Therapeutics’ antidepressant REL-1017 demonstrated rapid and sustained therapeutic effects in an open label, registrational Phase III trial (NCT04855760); Philippa Salter, Senior Neurology Analyst at GlobalData, offers her view: “Whilst these positive results are important for Relmada Therapeutics in demonstrating the efficacy of REL-1017 as an adjunctive therapy for major depressive […]
Read more

Genexine’s GX-E4 holds potential to change renal anemia treatment landscape in APAC, says GlobalData

Genexine recently released positive interim findings from the Phase III clinical trial of GX-E4 (Efepoetin alfa) for anemia induced by chronic kidney disease (CKD) or renal anemia in non-dialysis patients. Interim analysis confirms GX-E4 is non-inferior to Roche’s Mircera, a third-generation long-acting anemia treatment. As it advances towards regulatory submission in various APAC countries, Genexine […]
Read more

Eli Lilly’s Mounjaro to become leading GLP-1 therapy for type 2 diabetes in NHS in UK, says GlobalData

Eli Lilly received approval for its dual glucagon-like peptide-1 receptor agonist (GLP-1)/gastric inhibitor polypeptide receptor agonist (GIP) therapy Mounjaro (tirzepatide) in August 2023 for use as a new treatment option for patients in England with type 2 diabetes (T2D), in cases where the existing treatment management options are insufficient. With the recent clinical data that […]
Read more
1 … 28 29 30 31 32 … 108